Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: scott_jiminez who wrote (962)	1/31/2000 12:41:00 PM
From: Pseudo Biologist	Respond to of 4474

It sure makes more sense to add "fail-safe" to non-ARGENT forms of gene therapy. Licensing for general clinical applications simply shifts the burden of handling all these "unclear" issues from Ariad to the partner; so I still think is worthwhile to spend some time thinking about this. As for benchtop applications, sure. For an example of this see the recent PR from CEGE on letting a reagents company, Clontech?, distribute reagents for lab use. quicken.com Would love to see (a bunch of) deals like that from Ariad. Potential may be quite a bit larger than the CEGE technology, as we have discussed here. An interesting one for the "bundling" may be gene-activation of endogenous promoters a la TKTX. But I really do not know the competitive landscape here, so this is hand waving. PB